News

Researchers have developed a novel approach to detect amyotrophic lateral sclerosis (ALS) and predict survival outcomes in patients by measuring genetic activity in blood cells, according to a study. The scientists also built on their genetic activity analysis to define biological pathways that are disrupted in ALS and identify…

AMX0114, being developed as an amyotrophic lateral sclerosis (ALS) medication, has been well tolerated in early clinical testing, and a second group of patients will now test a higher dose of the experimental treatment. The first group of 12 participants enrolled in the Phase 1 LUMINA clinical trial…

Neurosense Therapeutics is gearing up to submit an application to Health Canada for approval of PrimeC to treat amyotrophic lateral sclerosis (ALS). The company said it had a “productive discussion” with Health Canada, during which the agency confirmed that Neurosense’s proposed next steps align with its expectations. A…

Actor Eric Dane is teaming up with Target ALS on a campaign to raise $500,000 by Dec. 31 to advance research on amyotrophic lateral sclerosis (ALS). Dane, who was diagnosed with ALS last year, has become a strong advocate for research. He portrayed a character with…

An ALS Association grant totaling nearly $1 million will support a clinical trial testing Pasithea Therapeutics‘ PAS-004 in people with amyotrophic lateral sclerosis (ALS). Funding for the Phase 1 trial is provided by the ALS Association’s Hoffman ALS Clinical Trial Awards Program, an initiative designed to support early…

Clene is planning to submit an application to the U.S. Food and Drug Administration (FDA) in early 2026 requesting accelerated approval of its oral therapy CNM-Au8 for treating amyotrophic lateral sclerosis (ALS). The company’s announcement follows new, positive data — from FDA-requested analyses — showing that CNM-Au8…

A Phase 2 clinical trial to investigate Tiziana Life Sciences’ intranasal foralumab for the treatment of amyotrophic lateral sclerosis (ALS) has been accepted into the Healey ALS MyMatch program at Massachusetts General Hospital. The program, located at the Sean M. Healey & AMG Center for ALS, is a…

The U.S. Food and Drug Administration (FDA) has authorized Neurosense Therapeutics to begin a pivotal Phase 3 trial of its experimental oral therapy PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). The authorization follows the FDA’s positive feedback on the design of the PARAGON trial and…

The ALS Association is awarding $20,000 grants to 107 eligible clinics across the U.S. to help strengthen multidisciplinary care for people living with amyotrophic lateral sclerosis (ALS) and their families. The funding — totaling $2.14 million — comes from the Hugh and Herbert Hoffman ALS Impact Fund,…

The ALS Network, in collaboration with ALS United, has announced the winners of the 2025 Research Innovation Grants, which support projects aimed at enhancing understanding and care for amyotrophic lateral sclerosis (ALS). This year’s group of 13 awarded research…